Baricitinib - CAS 1187594-09-7
Catalog number: B0084-457382
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C16H17N7O2S
Molecular Weight:
371.419
COA:
Inquire
Targets:
JAK
Description:
Baricitinib is a selective and orally bioactive inhibitor of JAK1 and JAK2. Baricitinib inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concentrations <50 nM. Baricitinib has been approved by FDA for the treatment of rheumatoid arthritis (RA).
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-457382 1 g $199 In stock
Bulk Inquiry
Brife Description:
JAK1/JAK2 inhibitor
Purity:
≥98%
Appearance:
White to Off-White Solid
Synonyms:
INCB028050; INCB 028050; INCB-028050; LY3009104; LY 3009104; LY-3009104; 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile; Olumiant
MSDS:
Inquire
Application:
the treatment of rheumatoid arthritis (RA)
Melting Point:
212-215°C
InChIKey:
XUZMWHLSFXCVMG-UHFFFAOYSA-N
InChI:
InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
Canonical SMILES:
CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
1.Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
Keystone EC1, Taylor PC2, Drescher E3, Schlichting DE4, Beattie SD4, Berclaz PY4, Lee CH4, Fidelus-Gort RK5, Luchi ME5, Rooney TP4, Macias WL4, Genovese MC6. Ann Rheum Dis. 2015 Feb;74(2):333-40. doi: 10.1136/annrheumdis-2014-206478. Epub 2014 Nov 27.
OBJECTIVES: To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid arthritis (RA) despite treatment with methotrexate.
2.Baricitinib in Patients with Refractory Rheumatoid Arthritis.
Genovese MC1, Kremer J1, Zamani O1, Ludivico C1, Krogulec M1, Xie L1, Beattie SD1, Koch AE1, Cardillo TE1, Rooney TP1, Macias WL1, de Bono S1, Schlichting DE1, Smolen JS1. N Engl J Med. 2016 Mar 31;374(13):1243-52. doi: 10.1056/NEJMoa1507247.
BACKGROUND: In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced disease activity in patients with rheumatoid arthritis who had not previously received treatment with biologic disease-modifying antirheumatic drugs (DMARDs).
3.Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.
Jabbari A1, Dai Z1, Xing L2, Cerise JE1, Ramot Y3, Berkun Y4, Sanchez GA5, Goldbach-Mansky R5, Christiano AM6, Clynes R7, Zlotogorski A3. EBioMedicine. 2015 Feb 26;2(4):351-5. doi: 10.1016/j.ebiom.2015.02.015. eCollection 2015.
BACKGROUND: Alopecia areata (AA) is an autoimmune disease resulting in hair loss with devastating psychosocial consequences. Despite its high prevalence, there are no FDA-approved treatments for AA. Prior studies have identified a prominent interferon signature in AA, which signals through JAK molecules.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related JAK Products


CAS 457081-03-7 Pyridone 6

Pyridone 6
(CAS: 457081-03-7)

Pyridone 6 is a potent and selective inhibitor of JAK1, JAK2, JAK3, and Tyk2, displaying significantly weaker affinities for other protein tyrosine kinases. It ...

CAS 1262832-74-5 PF-956980

PF-956980
(CAS: 1262832-74-5)

PF-956980, a close analogue of Tofacitinib, is a JAK3-selective inhibitor used as an anti-inflammatory agent. Besides, some studies showed that PF-956980 striki...

CAS 540737-29-9 Tofacitinib Citrate

Tofacitinib Citrate
(CAS: 540737-29-9)

Tofacitinib (trade name Xeljanz, formerly tasocitinib, CP-690550) is a drug discovered and developed by Pfizer. It is currently approved for the treatment of rh...

CAS 1208319-27-0 Oclacitinib maleate

Oclacitinib maleate
(CAS: 1208319-27-0)

Oclacitinib maleate was the first selective Janus kinase (JAK) inhibitor to be developed for dogs. Oclacitinib is most potent at inhibiting JAK1 (IC50=10 nM).

CAS 1206161-97-8 Filgotinib

Filgotinib
(CAS: 1206161-97-8)

Filgotinib, also known as GLPG0634, is a potent and selective JAK1 inhibitor. Filgotinib displayed a selectivity of 30-fold for JAK1- over JAK2-dependent signal...

CAS 1310726-60-3 Upadacitinib

Upadacitinib
(CAS: 1310726-60-3)

Upadacitinib is a selective JAK inhibitor under the development of AbbVie.ABT-494 is nearly 74 fold selective for Jak1 over Jak2 in cellular assays dependent on...

CAS 945755-56-6 XL019

XL019
(CAS: 945755-56-6)

XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1. It shows good biochemical and cellular potency against JAK2 ...

CAS 882405-89-2 BBT594

BBT594
(CAS: 882405-89-2)

BBT594, also called as NVP-BBT594, a dihydroindole compound, originally developed as an inhibitor of wild-type and T315I-mutant BCR–ABL1, and then subsequently ...

Chemical Structure

CAS 1187594-09-7 Baricitinib

Quick Inquiry

Verification code

Featured Items